GlassScriptPhysician profile
Sarah L Brewer
NPI 1902829963
$2,245.43
in general payments reported to CMS, 2019-2025
28 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $84.16 · 2021: $143 · 2022: $269 · 2023: $218 · 2024: $379 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $891 · Food and Beverage: $718 · Consulting Fee: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $891.14 |
| Food and Beverage | $717.93 |
| Consulting Fee | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $891.14 | 2025 | Pentax Medical |
| Medtronic, INC. | $206.10 | 2022-2024 | Nuro, Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.30 | 2022-2025 | Jardiance |
| Abbvie INC. | $101.20 | 2021-2025 | Vraylar |
| Mylan Specialty L.P. | $96.46 | 2020-2024 | Yupelri |
| Pfizer INC. | $93.75 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.14 | 2022-2023 | |
| Lilly USA, LLC | $69.22 | 2020-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $68.64 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.65 | 2023-2024 | |
| Viatris Specialty LLC | $39.85 | 2025 | Yupelri |
| Abbott Laboratories | $39.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $33.58 | 2020-2024 | Eliquis |
| Amarin Pharma, INC. | $30.06 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.64 | 2021-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $26.48 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $23.85 | 2022 | |
| Daiichi Sankyo INC. | $23.77 | 2021 | |
| Insulet Corporation | $22.04 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $18.93 | 2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $18.23 | 2024 | Voquezna |
| Astellas Pharma US INC | $17.69 | 2025 | Veozah |
| Boston Scientific Corporation | $17.27 | 2025 | Watchman Access System |
| Glaxosmithkline, LLC. | $15.94 | 2025 | Shingrix |
| Amgen INC. | $14.87 | 2025 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2021 | |
| Baxter Healthcare | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.